secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2022-07-14T23:59:59+00:00
Accession:  0001200375-22-000026
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis signs 10-year supply deal with Pfizer for PAXLOVID enzyme CDX-616; receives $25.9M retainer
--------------------------------------------------------------------------------

- Supply Agreement covers Codexis enzyme CDX-616 used in Pfizer's PAXLOVID (nirmatrelvir).
- Pfizer pays $25.9M retainer fee by July 31, 2022; up to 90% creditable against future orders through 2023.
- Revenue recognition: nominal portion in 2022, remainder in 2023-2024.
- No minimum purchase commitments; Codexis must maintain sufficient inventory for estimated Pfizer orders.
- Pfizer may terminate on 180 days' notice; term of 10 years with 3-year renewal options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000120037522000026/0001200375-22-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000120037522000026/cdxs-20220714.htm
  HTML page:      https://secwatch.observer/filing/0001200375-22-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer